News Image

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Provided By GlobeNewswire

Last update: Jun 20, 2025

NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET. To register for the event, please click here.

Read more at globenewswire.com

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (7/23/2025, 4:04:01 PM)

After market: 21.89 0 (0%)

21.89

+0.33 (+1.53%)



Find more stocks in the Stock Screener

Follow ChartMill for more